Literature DB >> 19508680

Problems in diagnosing atypical Gitelman's syndrome presenting with normomagnesaemia.

Akinobu Nakamura1, Chikara Shimizu, So Nagai, Masahiro Yoshida, Kazutaka Aoki, Takuma Kondo, Hideaki Miyoshi, Norio Wada, Toshihiro Tajima, Yasuo Terauchi, Narihito Yoshioka, Takao Koike.   

Abstract

OBJECTIVE: Gitelman's syndrome, recognized as a variant of Bartter's syndrome, is characterized by hypokalaemic metabolic alkalosis in combination with hypomagnesaemia and hypocalciuria. Overlapping biochemical features in Gitelman's syndrome and Bartter's syndrome has been observed. Here, we investigated the clinical, biochemical, and genetic characteristics of five, chronic, nonhypertensive and hypokalaemic Japanese patients.
METHODS: Serum and urinary electrolytes, plasma renin activity and plasma aldosterone concentration were measured in five patients (four males and one female) with hypokalaemia. Renal clearance tests were performed and distal fractional chloride reabsorption calculated. Finally, mutational analysis of the thiazide-sensitive Na-Cl co-transporter gene was performed.
RESULTS: Symptoms in patients varied from mild (muscle weakness and numbness) to severe (tetany and foot paralysis). All patients were normotensive or hypotensive, and all had hypokalaemia, hypocalciuria, and hyperreninaemic hyperaldosteronism. However, two male patients had normomagnesaemia, while the remainder was hypomagnesaemic. Renal clearance tests showed that the administration of furosemide decreased distal fractional chloride reabsorption, while thiazide ingestion failed to decrease it. Genetic analysis identified six thiazide-sensitive Na-Cl co-transporter gene mutations, including two novel ones. Therefore, on the basis of the confirmatory renal clearance tests and mutational analysis, a diagnosis of Gitelman's syndrome was made in these patients.
CONCLUSIONS: Two of the five patients diagnosed with Gitelman's syndrome were normomagnesaemic, which is uncommon in this syndrome. Our study indicates that renal clearance tests and mutation analysis can play an important role in diagnosing Gitelman's syndrome more precisely.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19508680     DOI: 10.1111/j.1365-2265.2009.03649.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  5 in total

1.  Cryptic exon activation in SLC12A3 in Gitelman syndrome.

Authors:  Kandai Nozu; Yoshimi Nozu; Keita Nakanishi; Takao Konomoto; Tomoko Horinouchi; Akemi Shono; Naoya Morisada; Shogo Minamikawa; Tomohiko Yamamura; Junya Fujimura; Koichi Nakanishi; Takeshi Ninchoji; Hiroshi Kaito; Ichiro Morioka; Mariko Taniguchi-Ikeda; Igor Vorechovsky; Kazumoto Iijima
Journal:  J Hum Genet       Date:  2016-10-27       Impact factor: 3.172

2.  Concurrence of thyrotoxicosis and Gitelman's syndrome-associated hypokalemia-induced periodic paralysis.

Authors:  Shinsaku Imashuku; Tomoko Teramura-Ikeda; Naoko Kudo; Shigehiro Kaneda; Toshihiro Tajima
Journal:  Pediatr Rep       Date:  2012-04-02

3.  Gitelman syndrome in a South African family presenting with hypokalaemia and unusual food cravings.

Authors:  Pieter Du Toit van der Merwe; Megan A Rensburg; William L Haylett; Soraya Bardien; M Razeen Davids
Journal:  BMC Nephrol       Date:  2017-01-26       Impact factor: 2.388

4.  Hydrochlorothiazide Test as a Tool in the Diagnosis of Gitelman Syndrome in Chinese Patients.

Authors:  Xiaoyan Peng; Bingbin Zhao; Lei Zhang; Lanping Jiang; Tao Yuan; Ying Wang; Haiyun Wang; Jie Ma; Naishi Li; Ke Zheng; Min Nie; Xuemei Li; Xiaoping Xing; Limeng Chen
Journal:  Front Endocrinol (Lausanne)       Date:  2018-09-24       Impact factor: 5.555

5.  Clinical and Genetic Characteristics in Patients With Gitelman Syndrome.

Authors:  Junya Fujimura; Kandai Nozu; Tomohiko Yamamura; Shogo Minamikawa; Keita Nakanishi; Tomoko Horinouchi; China Nagano; Nana Sakakibara; Koichi Nakanishi; Yuko Shima; Kenichi Miyako; Yoshimi Nozu; Naoya Morisada; Hiroaki Nagase; Takeshi Ninchoji; Hiroshi Kaito; Kazumoto Iijima
Journal:  Kidney Int Rep       Date:  2018-09-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.